NCT06764251View on ClinicalTrials.gov

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions

Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Tislelizumab + SOX

tislelizumab combined with SOX

All Listed Sponsors

lead

Liaoning Cancer Hospital & Institute

OTHER